European Case Law Identifier: | ECLI:EP:BA:2013:T052010.20130611 | ||||||||
---|---|---|---|---|---|---|---|---|---|
Date of decision: | 11 June 2013 | ||||||||
Case number: | T 0520/10 | ||||||||
Application number: | 93917891.9 | ||||||||
IPC class: | C12N 15/13 | ||||||||
Language of proceedings: | EN | ||||||||
Distribution: | D | ||||||||
Download and more information: |
|
||||||||
Title of application: | Protein expression system | ||||||||
Applicant name: | Celltech Therapeutics Limited | ||||||||
Opponent name: | Genentech, Inc. Monsanto Company Novartis Vaccines and Diagnostics, Inc. |
||||||||
Board: | 3.3.08 | ||||||||
Headnote: | - | ||||||||
Relevant legal provisions: |
|
||||||||
Keywords: | Lapse of patent in all designated states (yes) Patent proprietor sole appellant No request by patent proprietor to continue appeal proceedings Termination of appeal proceedings |
||||||||
Catchwords: |
- |
||||||||
Cited decisions: |
|
||||||||
Citing decisions: |
|
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t100520eu1.html
Date retrieved: 17 May 2021
7 references found.
Click X to load a reference inside the current page, click on the title to open in a new page.EPC Implementing Rules
XR.84 EPC Continuation of the opposition proceedings by the European Patent Office of its own motion